US COVID Vaccine Showing Success In Early Trials, Entering Next Phase Of Research
Moderna Therapeutics, a biotechnology group based in Cambridge, Massachusetts, announced Monday that its early human trials in 45 subjects for a potential vaccine to combat the novel coronavirus is showing signs of success and the company is moving forward with the next phase of research.
“These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 µg,” said Tal Zaks, M.D., Ph.D., Chief Medical Officer at Moderna. “When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials.”
The Trump Administration recently launched “Operation Warp Speed” to fast-track the vaccine’s development, which Trump and other experts on his Coronavirus Task Force say could be ready in 12-18 months.
“With today’s positive interim Phase 1 data and the positive data in the mouse challenge model, the Moderna team continues to focus on moving as fast as safely possible to start our pivotal Phase 3 study in July and, if successful, file a BLA,” said Stéphane Bancel, Chief Executive Officer at Moderna. “We are investing to scale up manufacturing so we can maximize the number of doses we can produce to help protect as many people as we can from SARS-CoV-2.”